Grace Therapeutics (GRCE) Competitors $2.97 +0.01 (+0.34%) As of 08/6/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock GRCE vs. ENTA, KYTX, BDTX, LFVN, ALEC, BIOA, NVCT, PBYI, CTNM, and NKTXShould you be buying Grace Therapeutics stock or one of its competitors? The main competitors of Grace Therapeutics include Enanta Pharmaceuticals (ENTA), Kyverna Therapeutics (KYTX), Black Diamond Therapeutics (BDTX), Lifevantage (LFVN), Alector (ALEC), BioAge Labs (BIOA), Nuvectis Pharma (NVCT), Puma Biotechnology (PBYI), Contineum Therapeutics (CTNM), and Nkarta (NKTX). These companies are all part of the "pharmaceutical products" industry. Grace Therapeutics vs. Its Competitors Enanta Pharmaceuticals Kyverna Therapeutics Black Diamond Therapeutics Lifevantage Alector BioAge Labs Nuvectis Pharma Puma Biotechnology Contineum Therapeutics Nkarta Grace Therapeutics (NASDAQ:GRCE) and Enanta Pharmaceuticals (NASDAQ:ENTA) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, profitability, dividends, institutional ownership, valuation, analyst recommendations, earnings and media sentiment. Is GRCE or ENTA more profitable? Grace Therapeutics has a net margin of 0.00% compared to Enanta Pharmaceuticals' net margin of -149.57%. Grace Therapeutics' return on equity of -19.45% beat Enanta Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Grace TherapeuticsN/A -19.45% -16.99% Enanta Pharmaceuticals -149.57%-79.83%-26.65% Does the media prefer GRCE or ENTA? In the previous week, Enanta Pharmaceuticals had 3 more articles in the media than Grace Therapeutics. MarketBeat recorded 3 mentions for Enanta Pharmaceuticals and 0 mentions for Grace Therapeutics. Enanta Pharmaceuticals' average media sentiment score of 0.99 beat Grace Therapeutics' score of 0.00 indicating that Enanta Pharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment Grace Therapeutics Neutral Enanta Pharmaceuticals Positive Which has better valuation and earnings, GRCE or ENTA? Grace Therapeutics has higher earnings, but lower revenue than Enanta Pharmaceuticals. Grace Therapeutics is trading at a lower price-to-earnings ratio than Enanta Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGrace TherapeuticsN/AN/A-$9.57M-$0.89-3.34Enanta Pharmaceuticals$67.64M2.25-$116.04M-$4.54-1.57 Do institutionals & insiders hold more shares of GRCE or ENTA? 6.1% of Grace Therapeutics shares are owned by institutional investors. Comparatively, 95.0% of Enanta Pharmaceuticals shares are owned by institutional investors. 11.1% of Grace Therapeutics shares are owned by company insiders. Comparatively, 13.9% of Enanta Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Do analysts recommend GRCE or ENTA? Grace Therapeutics presently has a consensus target price of $12.00, suggesting a potential upside of 304.04%. Enanta Pharmaceuticals has a consensus target price of $21.33, suggesting a potential upside of 199.63%. Given Grace Therapeutics' higher possible upside, equities analysts plainly believe Grace Therapeutics is more favorable than Enanta Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Grace Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Enanta Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more volatility & risk, GRCE or ENTA? Grace Therapeutics has a beta of 0.72, indicating that its share price is 28% less volatile than the S&P 500. Comparatively, Enanta Pharmaceuticals has a beta of 0.88, indicating that its share price is 12% less volatile than the S&P 500. SummaryEnanta Pharmaceuticals beats Grace Therapeutics on 8 of the 14 factors compared between the two stocks. Get Grace Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GRCE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GRCE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GRCE vs. The Competition Export to ExcelMetricGrace TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$41M$3.01B$5.57B$9.47BDividend YieldN/A2.41%4.31%4.13%P/E Ratio-3.3416.5729.3723.99Price / SalesN/A314.79444.1896.63Price / CashN/A42.1735.8458.51Price / Book0.617.818.085.58Net Income-$9.57M-$54.52M$3.26B$265.35M7 Day Performance2.77%0.41%0.45%-0.07%1 Month Performance-1.00%9.93%4.83%1.76%1 Year PerformanceN/A15.18%30.28%25.39% Grace Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GRCEGrace TherapeuticsN/A$2.97+0.3%$12.00+304.0%N/A$41MN/A-3.34N/AUpcoming EarningsENTAEnanta Pharmaceuticals3.801 of 5 stars$7.58-0.4%$18.50+144.1%-45.2%$162.68M$67.64M-1.67160Gap UpKYTXKyverna Therapeutics3.1119 of 5 stars$3.57-5.1%$15.60+337.0%-52.5%$162.50M$7.03M-1.0696News CoverageUpcoming EarningsBDTXBlack Diamond Therapeutics2.4409 of 5 stars$2.66-5.7%$12.80+381.2%-46.3%$160.35M$70M44.3390News CoveragePositive NewsLFVNLifevantage4.0727 of 5 stars$12.55-1.3%$30.50+143.0%+75.1%$160.12M$200.16M18.19260ALECAlector4.0627 of 5 stars$1.49-6.9%$4.17+179.6%-71.7%$159.99M$100.56M-1.18270BIOABioAge LabsN/A$4.40-0.5%N/AN/A$158.46MN/A0.00N/ANews CoveragePositive NewsEarnings ReportNVCTNuvectis Pharma2.4834 of 5 stars$6.96-7.8%$17.00+144.3%-2.4%$157.75MN/A-6.168News CoveragePositive NewsEarnings ReportAnalyst ForecastPBYIPuma Biotechnology3.8638 of 5 stars$3.11-1.6%$7.00+125.1%-19.4%$156.83M$230.50M4.04200CTNMContineum Therapeutics2.7948 of 5 stars$5.90-1.8%$22.50+281.4%-65.1%$155.49M$50M-2.9931News CoveragePositive NewsEarnings ReportUpcoming EarningsNKTXNkarta2.2667 of 5 stars$2.17-0.5%$14.33+560.5%-61.9%$154.69MN/A-1.44140Upcoming Earnings Related Companies and Tools Related Companies Enanta Pharmaceuticals Alternatives Kyverna Therapeutics Alternatives Black Diamond Therapeutics Alternatives Lifevantage Alternatives Alector Alternatives BioAge Labs Alternatives Nuvectis Pharma Alternatives Puma Biotechnology Alternatives Contineum Therapeutics Alternatives Nkarta Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GRCE) was last updated on 8/7/2025 by MarketBeat.com Staff From Our PartnersBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | Sponsored[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…Goldco Precious Metals | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredDigital Dollar Alert: Protect Your Wealth Before It’s Too Late134 countries are developing Central Bank Digital Currencies — and the U.S. is quietly testing one. Experts...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Grace Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Grace Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
